Suppression of weight gain by glucagon in obese Zucker rats

Eve K. Chan, Maureen A. Mackey, Dale C. Snover, Philip D Schneider, Richard D. Rucker, C. Eugene Allen, Henry Buchwald

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.

Original languageEnglish (US)
Pages (from-to)320-327
Number of pages8
JournalExperimental and Molecular Pathology
Volume40
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Zucker Rats
Glucagon
Weight Gain
Rats
Body Weight
Weights and Measures
Liver
Creatinine
Obesity
Weight control
Lipids
Glucose
Liver Glycogen
Aspartate Aminotransferases
Ketones
Serum
Glycogen
Alkaline Phosphatase
Urea
Animals

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Pathology and Forensic Medicine

Cite this

Chan, E. K., Mackey, M. A., Snover, D. C., Schneider, P. D., Rucker, R. D., Eugene Allen, C., & Buchwald, H. (1984). Suppression of weight gain by glucagon in obese Zucker rats. Experimental and Molecular Pathology, 40(3), 320-327. https://doi.org/10.1016/0014-4800(84)90049-2

Suppression of weight gain by glucagon in obese Zucker rats. / Chan, Eve K.; Mackey, Maureen A.; Snover, Dale C.; Schneider, Philip D; Rucker, Richard D.; Eugene Allen, C.; Buchwald, Henry.

In: Experimental and Molecular Pathology, Vol. 40, No. 3, 1984, p. 320-327.

Research output: Contribution to journalArticle

Chan, EK, Mackey, MA, Snover, DC, Schneider, PD, Rucker, RD, Eugene Allen, C & Buchwald, H 1984, 'Suppression of weight gain by glucagon in obese Zucker rats', Experimental and Molecular Pathology, vol. 40, no. 3, pp. 320-327. https://doi.org/10.1016/0014-4800(84)90049-2
Chan, Eve K. ; Mackey, Maureen A. ; Snover, Dale C. ; Schneider, Philip D ; Rucker, Richard D. ; Eugene Allen, C. ; Buchwald, Henry. / Suppression of weight gain by glucagon in obese Zucker rats. In: Experimental and Molecular Pathology. 1984 ; Vol. 40, No. 3. pp. 320-327.
@article{4ca06c74f742402c86c86ccc23158e76,
title = "Suppression of weight gain by glucagon in obese Zucker rats",
abstract = "Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20{\%}) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.",
author = "Chan, {Eve K.} and Mackey, {Maureen A.} and Snover, {Dale C.} and Schneider, {Philip D} and Rucker, {Richard D.} and {Eugene Allen}, C. and Henry Buchwald",
year = "1984",
doi = "10.1016/0014-4800(84)90049-2",
language = "English (US)",
volume = "40",
pages = "320--327",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Suppression of weight gain by glucagon in obese Zucker rats

AU - Chan, Eve K.

AU - Mackey, Maureen A.

AU - Snover, Dale C.

AU - Schneider, Philip D

AU - Rucker, Richard D.

AU - Eugene Allen, C.

AU - Buchwald, Henry

PY - 1984

Y1 - 1984

N2 - Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.

AB - Glucagon has been shown to lower blood lipids and to decrease food intake and body weight in short-term studies in man and animals. There is evidence of decreased secretion of glucagon in human obesity. The Zucker obese rat suffers from a genetic type of obesity and has an absolute reduction in circulating glucagon concentration. The effect of long-term administration of glucagon on the body weight in obese Zucker rats was studied. Glucagon caused a marked (-20%) reduction of body weight in obese Zucker rats with no change in feed intake. Urine glucose, urea nitrogen, creatinine, and ketone content, as well as serum triglyceride, cholesterol, alkaline phosphatase, creatinine, and insulin levels remained unchanged. Weights of perirenal fat, kidneys, and heart also remained unchanged. However, glucagon injection in obese Zucker rats caused significant decrease in serum glucose, and increases in SGOT, liver weight, and liver lipid and glycogen content. Further investigations are needed concerning the safety of chronic glucagon administration for weight control.

UR - http://www.scopus.com/inward/record.url?scp=0021261189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021261189&partnerID=8YFLogxK

U2 - 10.1016/0014-4800(84)90049-2

DO - 10.1016/0014-4800(84)90049-2

M3 - Article

C2 - 6723936

AN - SCOPUS:0021261189

VL - 40

SP - 320

EP - 327

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 3

ER -